CJ 12406

Drug Profile

CJ 12406

Alternative Names: CJ-12406

Latest Information Update: 09 May 2016

Price : $50

At a glance

  • Originator CJ Cheiljedang Corp.
  • Class
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Gastro-oesophageal reflux

Most Recent Events

  • 07 May 2013 Phase-I development is ongoing in South Korea
  • 30 Jun 2012 CJ Cheiljedang Corp. completes a phase I trial in healthy volunteers in South Korea (NCT01489774)
  • 11 Dec 2011 Phase-I clinical trials in Gastro-oesophageal reflux in South Korea (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top